A First-in-human Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Vaccine, After Intramuscular Administration in Healthy Subjects Aged 18-49 Years
Latest Information Update: 26 Mar 2025
At a glance
- Drugs OVX 033 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors OSIVAX
Most Recent Events
- 24 Mar 2025 Status changed from active, no longer recruiting to completed.
- 17 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jul 2024.
- 17 Jun 2024 Status changed from recruiting to active, no longer recruiting.